Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Mixed-Method Study for Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Units

10 november 2026 uppdaterad av: Peking University First Hospital

Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Unit Settings: A Mixed-Method Study

This is a phased mixed-method implementation study aiming to develop and evaluate a multi-component central-line-associated bloodstream infection (CLABSI) prevention bundle in three intensive-care units (Respiratory Intensive Care Unit, RICU; Surgical Intensive Care Unit, SICU; Neonatal Intensive Care Unit, NICU) at Peking University First Hospital. This study will first conduct pilot testing of the refined bundle in NICU, then scale-up implementation across all three ICUs. CLABSI incidence rate per 1000 central line-days is the primary outcome; bundle adherence rate and multi-dimensional implementation outcomes are secondary outcomes.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

1200

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100034
        • Rekrytering
        • Peking University First Hospital
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Liuyi Li, MMSc
        • Huvudutredare:
          • Hongling Chu, Ph.D.
        • Huvudutredare:
          • Xi Yao, MMSc
        • Underutredare:
          • Meihua Hu, MMSc
        • Underutredare:
          • Yuan Cheng, M.D.
        • Underutredare:
          • Tian Sang, M.D.
        • Underutredare:
          • Cui Yuan, MMSc

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn
  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Admitted to RICU, SICU or NICU of Peking University First Hospital during study period
  2. Has an indwelling central venous catheter (CVC, non-tunneled), peripherally inserted central catheter (PICC), or umbilical venous catheter (UVC)
  3. Generates central-line-days within study observation window

Exclusion Criteria:

  1. CVC placed in external hospitals and not managed within the three participating ICUs
  2. Central-line-days generated outside study observation period

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: CLABSI Prevention Bundle Intervention Arm

Single-group intervention, implementing multi-component CLABSI prevention bundle in NICU, RICU and SICU with phased roll-out

A multi-component CLABSI prevention bundle with six core measures: (1) preferable insertion site selection, (2) hand hygiene, (3) maximum sterile barrier precautions, (4) catheter hub disinfection and insertion site care, (5) timely removal of non-essential catheters, and (6) implementation of a standardized checklist. The study adopts a phased implementation design: a pilot phase will first be conducted in NICU to test the bundle, identify implementation barriers, and refine local strategies; after optimization, the refined bundle will be rolled out across RICU, SICU and NICU. Local implementation teams will develop tailored action plans, monitor adherence, and iteratively optimize implementation strategies throughout the study.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
CLABSI incidence rate
Tidsram: Baseline through intervention period, up to 36 months

CLABSI cases per 1000 central-line-days, defined according to Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) criteria. Calculated as number of CLABSI events divided by total central-line-days multiplied by 1000, collected prospectively in RICU, SICU and NICU.

Baseline through intervention period, up to 36 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall CLABSI prevention bundle adherence score
Tidsram: Baseline through implementation period, up to 36 months

A composite adherence score calculated as the mean proportion of correctly performed elements across six core CLABSI-prevention bundle measures (hand hygiene, maximum sterile barrier precautions, preferable insertion site, disinfection and site care, nonessential catheter removal, and checklist completion), assessed by direct observation and chart review. The score is expressed as a single percentage ranging from 0% to 100%.

Baseline through implementation period, up to 36 months
Acceptability of the CLABSI prevention intervention bundle
Tidsram: Entire study duration, up to 36 months

Acceptability will be assessed through semi-structured interviews with healthcare professionals involved in implementation to explore perceptions of whether the intervention bundle is agreeable and satisfactory in routine clinical practice. Findings will be reported as qualitative themes and categories.

Entire study duration, up to 36 months
Fidelity of implementation of the intervention bundle - Quantitative assessment
Tidsram: Entire study duration, up to 36 months

The degree to which the intervention bundle is implemented as intended according to predefined implementation procedures, assessed by quantitative process indicators, case audits, and checklists. Fidelity will be reported as the proportion of predefined procedures correctly completed.

Entire study duration, up to 36 months
Fidelity of implementation of the intervention bundle - Qualitative assessment
Tidsram: Entire study duration, up to 36 months

The degree to which the intervention bundle is implemented as intended, assessed through semi-structured interviews with implementation stakeholders. Qualitative findings regarding barriers and facilitators to implementation fidelity will be reported as themes.

Entire study duration, up to 36 months
Feasibility of implementation of the intervention bundle
Tidsram: Entire study duration, up to 36 months

Feasibility will be assessed through semi-structured interviews with healthcare professionals to determine the extent to which the intervention bundle can be successfully implemented within participating intensive care units. Findings will be reported as qualitative themes describing barriers and facilitators to implementation.

Entire study duration, up to 36 months
Sustainability of implementation of the intervention bundle - Quantitative assessment
Tidsram: Entire study duration, up to 36 months

The extent to which implementation of the intervention bundle is maintained over time, assessed using quantitative process indicators. Sustainability will be reported as the proportion of bundle elements continued in routine clinical practice.

Entire study duration, up to 36 months
Sustainability of implementation of the intervention bundle - Qualitative assessment
Tidsram: Entire study duration, up to 36 months

The extent to which implementation of the intervention bundle is integrated into routine clinical practice over time, assessed through semi-structured interviews. Qualitative findings will be reported as themes.

Entire study duration, up to 36 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Shuo Li, M.D., Peking University First Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 november 2024

Primärt slutförande (Beräknad)

1 december 2026

Avslutad studie (Beräknad)

1 december 2026

Studieregistreringsdatum

Först inskickad

24 september 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

17 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 2024-197-002
  • 23-515 (Annat bidrag/finansieringsnummer: China Medical Board)
  • 2024研197-002 (Annan identifierare: Peking University First Hospital Ethics Committee)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual-participant data will not be shared publicly because of patient privacy restrictions and local institutional data security requirements. Aggregated study results may be published in peer-reviewed journals.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera